Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:47:01 EDT Sat 05 Oct 2024
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - http://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q0.15.89·6.720.36.49+0.071.11,409.08,7836,4336.49  6.57  6.466.91  3.1718:58:11Sep 3015 min RT 2¢

Recent Trades - Last 10 of 6433
Time ETExPriceChangeVolume
18:58:11Q6.500.081,000
16:45:12Q6.540.121
16:29:52Q6.440.02700
16:02:14Q6.490.07249
16:02:09Q6.490.072,336
16:01:42Q6.490.07987
16:01:21Q6.490.071,140
16:01:17Q6.490.072,142
16:01:13Q6.490.078,073
16:00:08Q6.490.07392

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-30 06:00U:MNKDNews ReleaseMore Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza(TM))
2024-09-18 06:15U:MNKDNews ReleaseMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
2024-09-10 16:30U:MNKDNews ReleaseMannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
2024-08-27 16:30U:MNKDNews ReleaseMannKind to Present at Upcoming Conferences
2024-08-14 08:00U:MNKDNews ReleaseKent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board
2024-08-07 08:00U:MNKDNews ReleaseMannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
2024-07-31 06:30U:MNKDNews ReleaseMannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
2024-07-30 16:30U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
2024-06-22 08:00U:MNKDNews ReleaseINHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions
2024-06-05 06:45U:MNKDNews ReleaseInhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
2024-05-29 08:45U:MNKDNews ReleasePulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
2024-05-29 08:45U:MNKDNews ReleaseMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
2024-05-08 16:19U:MNKDNews ReleaseMannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
2024-05-06 06:05U:MNKDNews ReleaseMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
2024-05-01 16:00U:MNKDNews ReleaseMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
2024-04-30 06:05U:MNKDNews ReleaseMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
2024-04-29 06:05U:MNKDNews ReleaseMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
2024-04-03 06:00U:MNKDNews ReleaseMannKind Repays Certain Debt Obligations
2024-03-26 16:05U:MNKDNews ReleaseMannKind Announces CFO Transition
2024-03-11 06:05U:MNKDNews ReleaseINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza(TM) Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps